| Revenue growth | 7% YoY consolidated growth. |
|---|---|
| Margins | Consolidated EBITDA margin dropped to 21% from 29% YoY. |
| Demand visibility | Strong; take-or-pay agreements for majority of new capacities. |
| Management confidence | High; citing steady core and new growth engines. |
Growth
Consolidated revenue up 7% YoY to ₹218.2 Cr; API revenue up 6% YoY to ₹215.3 Cr.
Outlook
₹1,000+ Cr capex invested; revenue from new business segments expected to commence in next 6-12 months.
Risks
Short-term PAT drag (down 53% YoY) due to ₹35 Cr opex/depreciation from pre-revenue new businesses.
Investor Presentation filed with BSE, NSE: SYMBIOTEC. Summary written with AI assistance from the document.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,003.35
- Market cap
- ₹6,447 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways
Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.
- Call
- Guides 20% growth
Symbiotec Pharmalab Results Update
Symbiotec Pharmalab released its Q1FY27 investor update. The company reported consolidated revenue of Rs. 218.2 Crore and PAT of Rs. 14.1 Crore for the period.
Symbiotec Pharmalab Q1 FY27 Results: Net Profit ₹14.1 Cr, Down 52.8% YoY
Symbiotec Pharmalab Ltd reported revenue from operations of ₹218.2 Cr (+7.4% YoY) and net profit of ₹14.1 Cr (-52.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹14.1 Cr · -52.8% YoY
Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab Ltd scheduled a board meeting for September 21, 2026, to consider financial results for the quarter ended June 30, 2026.
Symbiotec Pharmalab Share Pledge
Symbiotec Pharmalab promoters pledged 34.93 lakh shares (~5.44%) to debenture trustee Beacon Trusteeship. This Securitisation encumbrance secures the company's debenture issue.
Symbiotec Pharmalab Capital Structure Change
Mirae Asset Mutual Fund acquired 34,97,420 shares of Symbiotec Pharmalab Ltd. This open market purchase increased their stake from 0.78% to 6.22%.